| Document |
Document Title |
|
WO/2024/079748A1 |
The present invention provides novel salts of Aramchol with an improved water solubility, physicochemical stability and dissolution characteristics. Particularly, the present invention provides sodium, potassium, magnesium, calcium and z...
|
|
WO/2024/077793A1 |
The present invention relates to a compound based on oxidative stress and an anti-amyloid aggregation mechanism, a preparation method therefor, and a use thereof. The compound of the present invention has a structure represented by formu...
|
|
WO/2024/006537A9 |
The disclosure relates to methods of using bile acid derivatives for the treatment and/or prevention of cognitive disorders, diseases, or conditions.
|
|
WO/2024/058975A1 |
The present disclosure provides compounds, compositions, and methods, wherein the compounds include a modified cholic acid or a cholic acid component and at least a second component in which the second component is conjugated to the modi...
|
|
WO/2024/033287A1 |
The present invention relates to a compound having general Formula (I) (e.g., hydroxycholest-5-ene glycoside or its derivatives; (e.g., Compounds 1-3 or their derivatives or analogues thereof or Compound 4 or its derivatives or analogues...
|
|
WO/2024/025465A1 |
Disclosed herein are methods of obtaining ferulic acid. In one aspect, the present disclosure refers to a method of hydrolysing oryzanol to obtain ferulic acid, wherein the method comprises: i. hydrolysing an oryzanol-comprising material...
|
|
WO/2024/012317A1 |
A composition for resisting aging, and a use thereof or a method therefor. The pharmaceutical composition comprises a therapeutic agent X or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipien...
|
|
WO/2024/015201A1 |
The disclosure relates to a crystalline solid form of Compound 1. The disclosure also provides methods of preparing said crystalline solid form of Compound 1.
|
|
WO/2023/247563A1 |
A compound of formula (I-A), R1 in each occurrence is selected from H, optionally substituted C1-12 alkyl and optionally substituted C6-20 aryl; R2 in each occurrence is selected from optionally substituted C1-12 alkyl and optionally sub...
|
|
WO/2023/250185A1 |
The disclosure relates to Compound 1 and crystalline solid forms and solid dosage forms thereof. The disclosure also provides methods of preparing and methods of using said crystalline solid forms of Compound 1 and solid dosage forms the...
|
|
WO/2023/233346A1 |
The present invention relates to compounds having general formula ( I ) and to their uses for simultaneously modulating the bile acid receptors, FXR and GPBAR1, and the orphan receptor ROR gamma (RORγ) and thus to their use in the treat...
|
|
WO/2023/217237A1 |
Disclosed are a lipid compound having a general formula as shown, and a composition, preparation and use thereof. The lipid compound is a compound based on cholic acid or a derivative thereof, or a pharmaceutically acceptable salt thereo...
|
|
WO/2023/216423A1 |
Disclosed in the present invention are a lipid compound as represented by a general formula and a composition, and the preparation and the use thereof. The lipid compound of the present invention is a compound based on cholic acid or a d...
|
|
WO/2023/213540A1 |
The present invention relates to a process for the preparation of cholic acid derivatives, in particular of compounds of formula (V). The present invention also relates to compounds useful for the preparation of such derivatives.
|
|
WO/2023/207268A1 |
Provided is a synthesis method for deoxycholic acid, which synthesizes deoxycholic acid from plant-derived 9-OH-BA as the starting material by means of steps of side chain oxidation reaction, Wittig or Wittig-Horner reaction, dehydration...
|
|
WO/2023/192221A1 |
The present disclosure provides solid forms of sodium chenodeoxycholate (NaCDC), as well as compositions thereof and methods of using and preparing the same.
|
|
WO/2023/179721A1 |
The present invention provides a synthesis method for a 7-ketolithocholic acid or an intermediate thereof, which is prepared from a new intermediate I-1. According to the method, phytosterol degradation product bisnoralchol is used as a ...
|
|
WO/2023/181077A1 |
The present invention relates to a stable liquid pharmaceutical composition comprising Obeticholic acid or its salts and one or more pharmaceutically acceptable excipients and its process of preparation and its use for the treatment of a...
|
|
WO/2023/179724A1 |
Provided in the present invention is a method for synthesizing a 7-ketolithocholic acid intermediate, the method comprising preparing compound OB-1 in an amide solvent to obtain a 7-ketolithocholic acid intermediate OB. The method of the...
|
|
WO/2023/179062A1 |
The present invention relates to an extraction process for cholesterol. The extraction process comprises the following steps: adding a mixture to be extracted into n-hexane, and stirring same at a constant speed until the mixture is diss...
|
|
WO/2023/176822A1 |
The purpose of the present invention is to provide: a sterol compound capable of achieving excellent nucleic acid delivery efficiency when used in lipid compositions; and a lipid composition which is capable of achieving excellent nuclei...
|
|
WO/2023/173359A1 |
The present invention relates to a use of a compound and an extract derived from natural fungus Antrodia camphorata in the preparation of an FGF21 agonist and/or an RDH10 agonist.
|
|
WO/2023/173846A1 |
A steroid compound and a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. The structural formula of the steroid compound is as shown in formula I', wherein R is dimethylamino or methylamino. Th...
|
|
WO/2023/169372A1 |
A cucurbitacin B derivative, a preparation method therefor and a use thereof. The structure of the compound is shown in formula I. The cucurbitacin B derivative is easy to synthesize, has good anti-tumor and anti-inflammatory activity, a...
|
|
WO/2023/168974A1 |
A cholic acid derivative, a preparation method therefor, and an application thereof as a TGR5 allosteric agonist. using CA as a lead compound, modification is performed at positions 7, 12, and 24 thereof by means of a series of reactions...
|
|
WO/2023/081657A9 |
Methods of making cholic acid derivatives, particularly UDCA, from non-animal sources, having exceptional purity and therapeutic utility.
|
|
WO/2023/147640A1 |
The invention generally refers to pharmaceutical uses of tetracyclic terpene 3-ols, as an example lanosta-8,24-dien-3-ol, bearing polar and/or charged moieties, as anti-inflammatory, anti-cancer and analgesic agents via the inhibition of...
|
|
WO/2023/148764A1 |
The present invention is to design and develop novel synthetic cholic acid derivatives for treating autoimmune disorders/inflammatory conditions, process of synthesis of the compounds, compositions comprising the said compounds and use o...
|
|
WO/2023/147141A1 |
The present disclosure relates to a combination of an FXR agonist and a fibrate. Also disclosed is use of the combination for the treatment, amelioration or prevention of an FXR mediated disease or condition, such as primary biliary chol...
|
|
WO/2023/143402A1 |
Disclosed in the present invention are a steroid compound, a preparation method therefor, and an application thereof. The steroid compound can have a structure shown in formula I. The compound of the present invention has SREBP pathway i...
|
|
WO/2023/142890A1 |
Disclosed in the present invention is a synthesis method for high-purity cholesterol. The cholesterol is synthesized by using plant-derived 21-hydroxy-20-methylpregn-4-en-3-one, which is also referred to as bisnoralcohol or BA, as a raw ...
|
|
WO/2023/142888A1 |
Disclosed in the present invention is a method for synthesizing high-purity plant-derived cholesterol. By taking plant-derived 21-hydroxy-20-methylpregn-4-en-3-one, also called bisnoralcohol or BA, as a raw material, cholesterol is synth...
|
|
WO/2023/143399A1 |
Disclosed in the present invention are a steroid compound, and a preparation method therefor and an application thereof. The steroid compound may have a structure as shown in formula XXI, etc. The compound of the present invention has SR...
|
|
WO/2023/143400A1 |
Provided are a steroid compound, a preparation method therefor and a use thereof. The steroid compound may have a structure as shown in formula VI. The compound has SREBP pathway inhibitory activity, and can be used for preventing and/or...
|
|
WO/2023/143398A1 |
Disclosed in the present invention are a steroid and a preparation method therefor and an application thereof. The steroid may have a structure as shown in formula II. The compound of the present invention has SREBP pathway inhibitory ac...
|
|
WO/2023/137529A1 |
The present invention relates to compounds which are active against parasitic infections, such as protozoan parasite infections (including flagellate parasite infections, ciliate parasite infections, amoeba parasite infections and apicom...
|
|
WO/2023/138493A1 |
Disclosed are a crystal form of a high-stability nor-ursodeoxycholic berberine salt and a preparation method therefor, which relate to the field of pharmaceutical chemistry. The crystal form has the following structural formula. In X-ray...
|
|
WO/2023/118484A1 |
A drug on the basis of 7,19-epoxy steroids, containing a compound of the general formula (I) or a physiologically acceptable salt thereof, wherein R1 = H; methyl, aryl-CH2-, Rx-C(=O)- or Rx-O-C(=O)-; or R1O is dispensed with if there is ...
|
|
WO/2023/115742A1 |
Disclosed in the present invention are a brassinosteroid analog, a new crystal form, a preparation method, and the use. The chemical formula of the brassinosteroid analog is C27H46O7, the chemical name thereof is (20R,22R)-2β,3β,14α-1...
|
|
WO/2023/115741A1 |
Disclosed in the present invention are a novel brassinosteroid analogue, a novel crystalline form and a preparation method therefor and an application thereof. The chemical formula of the brassinosteroid analogue is C27H46O7, the chemica...
|
|
WO/2023/088308A1 |
A class of steroid derivatives, and a preparation method therefor, a pharmaceutical composition and the use thereof. The steroid derivative is represented by formula (I 0), and also comprises a hydrate, a solvate, an isotope derivative, ...
|
|
WO/2023/083343A1 |
Among other things, the present disclosure provides technologies, e.g., compounds, compositions, methods, use for preventing or treating various conditions, disorders or diseases. In some embodiments, a condition, disorder or disease is ...
|
|
WO/2023/081166A1 |
Methods of making 5.beta-steroids by stereoselective hydrogenation of the corresponding 4(5)-unsaturated starting compounds, said method employing a solvent comprising at least 10% of pyridine or a substituted pyridine.
|
|
WO/2023/081658A2 |
Methods of making cholic acid derivatives, particularly TUDCA, preferably from non- animal sources, having exceptional purity and therapeutic utility.
|
|
WO/2023/068376A1 |
Provided is a pharmaceutical composition which is effective as an anti-cancer immunostimulating therapy. Said pharmaceutical composition has a compound set forth in general formula (I) or a salt thereof as an active ingredient {in the fo...
|
|
WO/2023/049295A1 |
Deuterated compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. These compounds are contemplated as useful for the prevention and treatment o...
|
|
WO/2023/040879A1 |
Disclosed herein are drug delivery systems and methods for locally delivering therapeutic agents, and methods for using such drug delivery systems for the treatment of diseases.
|
|
WO/2023/030332A1 |
A steroidal compound, a preparation method therefor and an application thereof. On one hand, provided are a compound represented by formula I, a preparation method therefor, and an application thereof in a method for separating and purif...
|
|
WO/2023/028278A2 |
Compounds are provided according to Formulae (A-I), (B-I), (C-I), (D-I), (E-I), (F-I), (G-I), and (H-I) : and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present disclosure are con...
|
|
WO/2023/000135A1 |
Provided are new process and intermediates for preparing onapristone.
|
